Shield Therapeutics plc Cash Flow-to-Debt Ratio
Shield Therapeutics plc cash flow-to-debt ratio. Shield Therapeutics plc (STX) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2025, meaning its operating cash flow of GBX-4.49 Million could theoretically repay 0% of its total liabilities (GBX76.96 Million) in one year. Check Shield Therapeutics plc (STX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Shield Therapeutics plc (2014–2024)
Cash flow-to-debt ratio of Shield Therapeutics plc from 2014 to 2024. Historical debt coverage capacity for Shield Therapeutics plc across 11 annual periods. Check how aggressively does Shield Therapeutics plc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Shield Therapeutics plc Cash Flow-to-Debt Ratio by Year (2014–2024)
Shield Therapeutics plc cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Shield Therapeutics plc. For the full cash flow conversion analysis, see STX cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.15x | GBX-7.01 Million | GBX46.95 Million | ▲ +89.4% |
| 2023 | -1.40x | GBX-37.13 Million | GBX26.49 Million | ▼ -27.9% |
| 2022 | -1.10x | GBX-18.25 Million | GBX16.65 Million | ▲ +77.9% |
| 2021 | -4.95x | GBX-16.74 Million | GBX3.38 Million | ▼ -696.6% |
| 2020 | -0.62x | GBX-1.40 Million | GBX2.25 Million | ▲ +36.2% |
| 2019 | -0.97x | GBX-4.07 Million | GBX4.17 Million | ▼ -1515.0% |
| 2018 | -0.06x | GBX-178.00K | GBX2.95 Million | ▲ +98.6% |
| 2017 | -4.29x | GBX-16.15 Million | GBX3.76 Million | ▼ -66.9% |
| 2016 | -2.57x | GBX-10.26 Million | GBX3.99 Million | ▼ -1222.0% |
| 2015 | -0.19x | GBX-4.18 Million | GBX21.50 Million | ▼ -12.3% |
| 2014 | -0.17x | GBX-3.34 Million | GBX19.29 Million | — |